Perspective The failure of cholesteryl ester transfer protein inhibitors: Is it due to increased blood viscosity?

Therapeutic Advances in Cardiovascular Disease

Volumn 9, Issue 2, 2015, Pages 32-35

  Sloop, Gregory D ^a   Weidman, Joseph J ^b   cyr, John A St ^c  

^a Benefis Health System   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Jacqmar Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HYPOCHOLESTEROLEMIC AGENT; QUINOLINE DERIVATIVE; THIOL DERIVATIVE; TORCETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; BLOOD VISCOSITY; CARDIOVASCULAR DISEASES; DRUG EFFECTS; ERYTHROCYTE AGGREGATION; HUMAN; MORTALITY; TREATMENT FAILURE; AGING; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG TREATMENT FAILURE; ERYTHROCYTE MEMBRANE; HEART INFARCTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFE EXPECTANCY; METABOLIC SYNDROME X; MONOTHERAPY; NONHUMAN; OSMOTIC PRESSURE; OUTCOME ASSESSMENT; PARTICLE SIZE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SHEAR STRESS; SMOKING; STATIC ELECTRICITY; THROMBOSIS; TISSUE PERFUSION;

ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; BLOOD VISCOSITY; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; ERYTHROCYTE AGGREGATION; HUMANS; QUINOLINES; SULFHYDRYL COMPOUNDS; TREATMENT FAILURE;

EID: 84924864319     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944714566427     Document Type: Editorial

References (23)

1. Barter P. Caulfield M. Eriksson M. Grundy S. Kastelein J. Komajda M. (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109–2122.
2. Ballantyne C. Miller M. Niesor E. Burgess T. Kallend D. Stein E. (2012) Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein -composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J 163: 515–521.
3. Brousseau M. Schafer E. Wolfe M. Bloedon L. Digenio A. Clark R. et al. (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. New Eng J Med 350: 1505–1515.
4. Cannon C. Shah S. Dansky H. Davidson M. Brinton E. Gotto A. et al. (2010) Safety of anacetrapib in patients with or at high risk for coronary heart disease. New Eng J Med 363: 2406–2415.
5. Duguid J. (1960) The thrombogenic hypothesis and its implications. Postgrad Med J 36: 226–229.
6. El Harchaoui K. Arsenault B. Franssen R. Despres J. Hovingh G. Stroes E. et al. (2009) High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med 150: 84–93.
7. Holsworth R. Jr. Sloop G. Weidman J. (2013) Review of major epidemiologic studies of blood viscosity in cardiovascular diseases. IMCJ 12: 24–35.
8. Hui D. Noel J. Harmony J. (1981) Binding of plasma low density lipoproteins to erythrocytes. Biochim Biophys Acta 664: 513–526.
9. Illingworth D. (1993) Am J Kid Dis 22: 90–97.
10. Mohammadpour A. Akhlaghi F. (2013) Future of cholesterol ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin Pharmacokinet 52: 6156–6157.
11. Neu B. Meiselman H. (2002) Depletion-mediated red blood cell aggregation in polymer solutions. Biophys J 83: 2482–2490.
12. Niesor E. (2011) Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr Opin Lipidol 22: 288–295.
13. Schwartz G. Olsson A. Abt M. Ballantyne C. Barter P. Brumm J. (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367: 2089–2099.
14. Shinkai H. (2012) Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vasc Health Risk Manage 8: 323–331.
15. Sloop G. (1996) A unifying theory of atherogenesis. Med Hypotheses 47: 321–325.
16. Sloop G. (1999) A critical analysis of the role of cholesterol in atherogenesis. Atherosclerosis 142: 265–268.
17. Sloop G. Garber D. (1997) The effects of low-density lipoprotein and high-density lipoprotein on blood viscosity correlate with their association with risk of atherosclerosis in humans. Clin Sci 92: 473–479.
18. Sloop G. Holsworth R. Jr. Weidman J. St Cyr J. (2014) The role of chronic hyperviscosity in vascular disease. Ther Adv Cardiovasc Dis. DOI: 10.1177/1753944714553226.
19. Stary H. Chandler A. Dinsmore R. Fuster V. Glagov S. Insull W. Jr. et al. (1995) A definition of advanced types of atherosclerotic lesions and a histologic classification of atherosclerosis. Circulation 92: 1355–1374.
20. Toth P. Barter P. Rosenson R. Boden W. Chapman M. Cuchel M. et al. (2013) High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol 7: 484–525.
21. van der Steeg W. Holme I. Boekholdt S. Larsen M. Lindahl C. Stroes E. et al. (2008) High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk. J Am Coll Cardiol 51: 634–642.
22. van Oss D. Absolom D. (1983) Zeta potential, van der Waals force and hemagglutiniation. Vox Sang 44: 183–190.
23. Vivekananthan D. Penn M. Sapp S. Hsu A. Topol E. (2003). Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 361: 2017–2023.